TCI Wealth Advisors’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
Other funds holding VRDN
VA
PBA
CC
RCM
PA
VC
PCH
TCI Wealth Advisors's VRDN Position: Q2 2023 in Review
TCI Wealth Advisors sold out of Viridian Therapeutics (VRDN) in Q2 2023, closing a stake of 132 shares — an estimated $3.36K sold.
TCI Wealth Advisors first reported a position in VRDN in Q1 2023 and held it in 1 quarter. The position peaked at $3.36K in Q1 2023. 128 funds tracked by Wall St. Rank hold VRDN as of Q2 2023.
- TCI Wealth Advisors reported no remaining Viridian Therapeutics position as of Q2 2023 after selling out during the quarter.
- TCI Wealth Advisors sold 132 Viridian Therapeutics shares in Q2 2023, an estimated $3.36K.
- TCI Wealth Advisors first reported a position in Viridian Therapeutics in Q1 2023 and held it in 1 quarter.
- TCI Wealth Advisors's Viridian Therapeutics position peaked at $3.36K in Q1 2023.
- 128 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2023.
Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.